Product Description
A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28134290/)
Mechanisms of Action: HDAC Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: CrystalGenomics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Korea, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Adenocarcinoma|Myelodysplastic Syndrome|Pancreatic Cancer|Preleukemia
Phase 1: Healthy Volunteers|Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CG-745-2-08 | P2 |
Recruiting |
Pancreatic Cancer|Adenocarcinoma |
2025-02-01 |
57% |
| CG200745-1-02 | P1 |
Active, not recruiting |
Healthy Volunteers|Oncology Solid Tumor Unspecified|Oncology Hematological Unspecified |
2023-12-01 |
|
| CG200745-2-02 | P2 |
Active, not recruiting |
Myelodysplastic Syndrome|Preleukemia |
2022-12-01 |
24% |
| CG200745-2-02 | P2 |
Active, not recruiting |
Myelodysplastic Syndrome|Preleukemia |
2022-12-01 |
24% |
| CG200745-2-02 | P2 |
Active, not recruiting |
Myelodysplastic Syndrome|Preleukemia |
2022-12-01 |
24% |